Due to low toxicity but high and long-lasting response rates of CDK4/6 inhibition, these drugs should be used in all patients with hormonal receptor positive and HER2 negative advanced breast cancer until more reliable biomarkers become available [12–15]. Here, NR4A1 is linked to breast carcinoma.